To date, the evaluation of IDO1 inhibitors alone or combined with ICI in clinical trials have provided disillusioning results, requiring more comprehensive understandings on the role of Trp-Kyn-AhR pathway in cancer development and immunology. This evidence concerns the gene IDO1 and cancer.